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HIGH DOSE CHEMOTHERAPY FOLLOWED BY STEM CELL RESCUE IN AD-
OLESCENTS WITH EWING’S SARCOMA
Tatman, D.J., Rumelhart, S.L., Radhi, M.A. University of Iowa, Iowa
City, IA.
Ewing Sarcoma (ES) is the second most common bone tumor in
children and young adults. About two thirds of patients with local-
ized disease will have long term survival. However, patients with
metastatic disease at diagnosis and patients with progressive or re-
current disease have dismal chance of survival. High dose chemo-
therapy (HDC) followed by autologous stem cell rescue (ASCR)
has not been shown to be unequivocally helpful in a randomized
clinical trial. However, several smaller studies have shown clear
benefit for HDC in a subset of patients. In this case series we report
three consecutive patients with recurrent ES. Each subject or guard-
ian signed an IRB-approved consent to participate in this study.
Two patients had localized recurrence of their disease while one pa-
tient had bone marrow involvement at recurrence. Patients received
carboplatin, etoposide (VP), cyclophosphamide (CPM) and topote-
can for salvage chemotherapy. Once a complete remission (CR) was
achieved, each patient went directly to transplant using a condition-
ing regimen of either CPM/VP/Thiotepa (TT) (UPN1) or Busul-
fan/Melphalan/TT (UPN2 and UPN3). The patient with positive
BM involvement was ES negative by PCR prior to transplant. These
regimens were well tolerated and none of the patients experienced
serious adverse events in the peri or post transplant periods. Median
graft size was 5.46 and range 3.0–10.0  106 CD341/Kg All pa-
tients had myeloid engraftment on a timely basis (range 11–13
days) and had a range in length of stay of 37–44 days. Median sur-
vival was 19 months, with range of 10–24 months. All patients are
alive and disease free to date. Following transplant, Lansky/Karnof-
sky scores were 80–90 at 2 months and all scores were $ 90 at 6
months. Conclusions that can be drawn from this small series in-
clude: 1) HDC followed by ASCR can be well tolerated; 2) durable
remission can be achieved following this therapy; and 3) trans-
planted patients can be expected to have good quality of life post
transplant.
Patient data
LengthPatient
ID
Age at
ASCRPrimary
site of
disease rSite of
ecurrence
Time to
relapse
(mo) ATime from
dx to
SCR (mo)Initial
therapy
pof CR
ost ASCR
(mo)UPN1 15 spine spine 47 54 Adria/VP/Ifos 24UPN2 14 nasal fossa spine 32 37 Vin/Adria/CPM 19UPN3 19 chest chest, BM 41 47 Vin/Adria/CPM 10Adria: Adriamycin; Vin: Vincristine; Ifos: Ifosfamide.
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OUTCOME OF ALLOGENEIC STEM CELL TRANSPLANTATION FOR 26
CHILDREN WITH MYELOID LEUKEMIA IN SINGLE CENTER
Chen, J., Jiang, H., Dong, L., Luo, C., Wang, Y. Shanghai Children’s
Medical Center, China.
Background & Objective: Children with acute myeloid leuke-
mia (AML) have poor prognosis. Treated with chemotherapy alone,
they can hardly survive if the disease is refractory or relapse. Al-
though the onset of chronic myeloid leukemia (CML) is relatively
slow and treatment with Gleevec will further prolong the survival
time, it still can not be cured by the targeting treatment. Allogeneic
hematopoietic stem cell transplantation will be the only way to cure
these diseases. The purpose of this paper was to clarify the role of
hematopoietic stem cell transplantation treating patients with mye-
loid leukemia. Methods: A total of 26 consecutive patients with
AML and CML in a single institution between May 2001 and Sep-
tember 2006 were included. Among them, 8 were chronic myeloid
leukemia (CP 5 5, AP 5 2, BP 5 1) and 18 were AML (CR1 5 9,
CR2 5 7, Non CR 5 2).5 out of 9 AML got CR1 after at least 2
courses of chemotherapy. The average age was 9.4 years old(range
2 years17 years)and the average body weight 32.8 kg (range 11.5kg79 kg), Patients underwent allogeneic peripheral blood stem
cell transplantation (allo-PBSCT) from HLA-identical siblings (n
5 2), mismatched family donors (n5 4), and matched unrelated do-
nors(n 5 20). All patients received myeloablative regimens with
1620 mg/kg busulfan and 200 mg/kg cyclophosphomide. For
aGVHD prophylaxis patients with HLA-identical sibling donors
received cyclosporine (CSA) and methetraxate, while patients with
matched unrelated donors received CSA, methotrexate and 15
mg/kg rabbit ATG(Fresenius). After Jan.2004 mycophenolate mo-
fetil were used to enhance GVHD prophylaxis for CML patients.
Results: After a average follow-up of 20.5 months(955 months),
2 (7.6%)patients graft rejected, 7 (27%) patients developed grade
34 aGVHD (all with CML), 5 patients having extensive cGVHD.
At present, 9 patients have died of relapse (4/26) and TRM (GVHD
4/26 and infection 1/26) while 17 (65%) patients are still alive with
disease-free survival. Conclusion: Our evidences is convincing that
allogeneic stem cell transplantation is conducive to improve the sur-
vival rate for children with acute myeloid leukemia and the GVHD
associated with unrelated donor transplants can be controlled after
take active prevention measures. As to whether the GVHD hap-
pened was more severe in children with CML than that of children
with AML, It still remain to have more patients and more institu-
tions collaboration to confirm such a conclusion.
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SUCCESSFUL COMBINED UNRELATED UMBILICAL CORD BLOOD HAP-
LOIDENTICAL TRANSPLANT IN NON MALIGNANT DISEASE
Kleiner, G.I.1, Barredo, J.1, Shariatmadar, S.1, Khan, A.2, Pahwa, R.2,
Rodriguez, M.1, Willumsen, S.1, Podda, A.1, Fernandes, C.1,
Alvarez, O.1, Kritzer-Cheren, M.1, Tzakis, A.1, Rubinstein, P.3,
Kurtzberg, J.4. 1 University of Miami Miller School of Medicine, Miami,
FL; 2 Diabetes Research Institue University of Miami, Miami, FL; 3 Na-
tional Cord Blood Program, New York, NY; 4 Duke Medical Center, Dur-
ham, NC.
Over the past decade, UCB transplantation has become a viable
alternative donor stem cell source for HSCT in patients with cata-
strophic diseases treatable with transplantation therapy. UCB cell
dose is the best predictor of outcomes after UCB transplantation.
In patients receiving lower cell doses, there are significant delays
and sometimes failures in myeloid and platelet engraftment. Com-
bined unit transplantation is currently under study to overcome
some of these barriers. We took an alternative approach to facilitate
early myeloid engraftment after myeloablative preparative condi-
tioning for a teenager with HLH and previous Aspergillus pneumo-
nia. Our hypothesis was that as the immunocompetent UCB cells
engrafted, the subject would reject the immunologically incompe-
tent haplo-identical HSCT graft and the patient would convert to
full UCB donor. We predicted faster myeloid engraftment in this
setting. A 15 year old boy with common variable immune deficiency
and HLH refractory to medical therapy underwent myeloablative
conditioning with standard TBI/CY/ATGAM and received a com-
posite graft consisting of a 1) 5/6 UCB which delivered 2.5  107
TNC/KG and 2) 2  106/KG CD34 selected PSSC collected
from the father. The subject engrafted on day 9. Initial chimerism
was predominantly (.80%) the haplo donor. This was followed
by an increase in UCB chimerism (.90% on D1 17). The subject
was fully reconstituted with UCB by D1 32. The subject later de-
veloped Grade IV GVHD of liver and intestine at the time of full
UCB engraftment that was treated with MSCs and liver transplan-
tation. This combined UCB/Haplo approach has the advantage of
faster myeloid engraftment than double UCB transplant in subjects
at high risk of infectious complications and or graft failure.242
UNRELATED CORD BLOOD TRANSPLANTATION (UCBT) IN PEDIATRIC
PATIENTS: A SINGLE CENTER EXPERIENCE IN CHILE
Barriga, F.J., Wietstruck, M.A., Zun˜iga, P. Catholic University of Chile,
Santiago, Chile.
Umbilical cord blood (CB) from unrelated donors is being used
increasingly in pediatric stem cell transplantation and it represents
